EPISODE · Oct 6, 2022 · 31 MIN
Psychedelics, Psychosis, and Risk Reduction
from Back from the Abyss: Psychiatry in Stories | Psychotherapy, Psychopharmacology, and Psychedelics · host Craig Heacock MD
This is a talk that Dr. H gave in Denver at the Nowak Society in Aug. 2022. Medicalization and/or legalization of psilocybin is likely coming to Colorado soon, with other psychedelics soon to follow. This will foster both a new era of psychiatric treatments and psychospiritual exploration, as well as a significant increase in adverse psychiatric events, including psychotic breaks. Dr. H explores the various classes of psychedelics (cannabinoids, tryptamines, phenethylamines, ketamine, e.g.) and assesses their relative risk of triggering psychosis, how and why polypharmacy (particularly with THC) greatly magnifies risk of developing psychosis, and the complex interplay between genetic vulnerability for psychosis/schizophrenia and the use of various psychoactive drugs. BFTA on Instagram. @backfromtheabysspodcasthttps://www.instagram.com/backfromtheabysspodcast/BFTA/ Dr. Hhttps://www.craigheacockmd.com/podcast-page/Support the show
Embed this episode
What this episode covers
This is a talk that Dr. H gave in Denver at the Nowak Society in Aug. 2022. Medicalization and/or legalization of psilocybin is likely coming to Colorado soon, with other psychedelics soon to follow. This will foster both a new era of psychiatric treatments and psychospiritual exploration, as well as a significant increase in adverse psychiatric events, including psychotic breaks. Dr. H explores the various classes of psychedelics (cannabinoids, tryptamines, phenethylamines, ketamine, e.g.)...
NOW PLAYING
Psychedelics, Psychosis, and Risk Reduction
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.